Higher risk due to health conditions

Complete COVID-19 vaccination series was associated with a reduced case fatality rate for patients with advanced CKD

A CTIF-funded study, published in the Clinical Journal of the American Society of Nephrology, showed that people with advanced Chronic Kidney Disease (CKD) who were double-vaccinated (at a time when only two doses were available) had markedly decreased fatality rates compared to CKD patients who had only one dose or no doses.

2023-12-12T10:38:20-05:00December 8, 2023|Higher risk due to health conditions|

COVID-19 vaccines are safe and offer protection against hospitalization for solid organ transplant recipients

A CITF-funded study, published in Open Forum Infectious Diseases, found that for solid organ transplant recipients (SOTRs), COVID-19 vaccines are safe, induce high levels of SARS-CoV-2 receptor binding domain (RBD) following a third dose (in most SOTRs), and offer protection from hospitalization.

2023-11-24T16:40:17-05:00November 24, 2023|Higher risk due to health conditions|

People living with HIV frequently practiced COVID-19 preventative behaviours

A CITF-funded study, published in AIDS Research and Therapy, found that people living with HIV (PLWH) in Canada displayed a high level of adherence to COVID-19 preventive behaviours, including masking, physical distancing, limiting social gatherings, limiting contact with at-risk individuals, self-isolating due to symptoms, and self-quarantining after possible exposure.

2023-11-12T19:40:24-05:00November 12, 2023|Higher risk due to health conditions|

Third mRNA vaccine dose induced strong humoral responses in participants with chronic kidney disease, with Moderna performing slightly better than Pfizer

A CITF-funded study, published in the Clinical Journal of the American Society of Nephrology, showed that a third dose of COVID-19 mRNA vaccine with  Moderna (monovalent) given to patients with chronic kidney disease (CKD) elicited higher SARS-CoV-2 anti-RBD levels than with the Pfizer (monovalent) vaccine over a six-month period.

2023-11-14T11:16:11-05:00November 12, 2023|Higher risk due to health conditions|

Pfizer (BA.4/BA.5) and Moderna (BA.1) bivalent vaccines induce similar neutralization against Omicron subvariants

A CITF-funded study, published in Nature Communications, found that Pfizer (BNT162b2 (BA.4/BA.5)) and Moderna (mRNA-1273 (BA.1)) bivalent vaccines induced similar neutralization to each other against Omicron subvariants BA.1, BA.5, BQ.1.1, and XBB.1.5 in patients on dialysis or with a kidney transplant, despite being antigenically divergent from strains circulating at the time.

2023-10-14T19:11:52-04:00October 14, 2023|Higher risk due to health conditions|

T-cell responses against Omicron variants BA.4/5 and XBB.1.5 in solid organ transplant recipients were robust after three doses of vaccine but lower than against the ancestral strain

A CITF-funded study, published in preprint and not yet peer-reviewed, found that vaccination induced robust SARS-CoV-2-specific T-cells responses against Omicron variant BA.4/5, in solid organ transplant recipients (SOTRs).

2023-09-19T11:54:56-04:00September 18, 2023|Higher risk due to health conditions|
Go to Top